Skip to main content
Premium Trial:

Request an Annual Quote

Febit Rises from the Ashes with New VC Cash; Geniom to Re-enter Market

NEW YORK, May 20 (GenomeWeb News) - Nineteen months after going out of business, microarray manufacturer Febit has re-emerged as a new company with fresh venture capital backing.


The new company, called Febit Biotech, was established in April. It is based in Heidelberg, Germany. Febit had been based in Mannheim. It rose from the ashes after two original Febit investors, Dietmar and Oliver Hopp, re-invested an undisclosed sum into the new firm.


Febit Biotech will "take over the Febit assets required to continue marketing" the Geniom One DNA analysis instrument, Febit's first product, the firm said in statement yesterday. "The newly founded company will also take care of existing Geniom customers."


Febit Biotech said it expects to begin manufacturing Geniom systems this summer.


As GenomeWeb News reported in October 2004, Febit had gone out of business just months after launching the Geniom instrument. The company filed for insolvency earlier in 2004 and proceedings had opened in July of that year.


Febit, founded in 1998, raised €30 million ($37 million in 2002 dollars) in a third round of private financing in late 2002. Among its investors were the EMBL Technology Fund and Infineon Ventures.

Geniom One was launched in late 2003. According to the firm, it could synthesize custom oligo arrays, perform experiments, and scan arrays all within the confines of the instrument. Febit had promised to launch the product by the end of 2002, but efforts to work out the bugs delayed the product's introduction by a year.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.